David Micklem

机构：The University of Texas at San Antonio Health Science Center, BerGenBio (Norway) · ORCID：0000-0003-2756-2591

发表论文 118 篇 · 总被引 3621 次 · h-index 23

代表论文

• Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer (2023 · Lung Cancer · 被引 41)
• AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy (2024 · Frontiers in Immunology · 被引 16)
• Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial (2025 · Nature Communications · 被引 15)
• AXL-TBK1 driven AKT3 activation promotes metastasis (2024 · Science Signaling · 被引 6)
• 1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) (2023 · Annals of Oncology · 被引 5)
• In vivo turnover and biodistribution of soluble AXL: implications for biomarker development (2024 · Scientific Reports · 被引 4)